Persistent URL of this record https://hdl.handle.net/1887/96560
In Collections
This item can be found in the following collections:
![Phase I/II clinical trial demonstrates feasibility, safety and effectivity of CMV-pp65-specific donor T-cells for the treatment of refractory CMV reactivation after allogeneic stem cell transplantation](https://scholarlypublications.universiteitleiden.nl/sites/all/themes/scholarly/img/closed_access.png)
Phase I/II clinical trial demonstrates feasibility, safety and effectivity of CMV-pp65-specific donor T-cells for the treatment of refractory CMV reactivation after allogeneic stem cell transplantation
- All authors
- Jedema, I.; Balen, P. van; Halkes, C.J.M.; Egmond, E.H.M. van; Liempt, E.A.G. van; Veld, S.A.J.; Hoogstraten, C.; Meij, P.; Kersting, S.; Zwaginga, J.J.; Rauser, G.; Assenmacher, M.; Falkenburg, J.H.F.
- Date
- 2018-09-30
- Journal
- Bone Marrow Transplantation
- Volume
- 53
- Pages
- 45 - 45